Stock Analysis
Epigral Full Year 2024 Earnings: EPS: ₹47.13 (vs ₹85.03 in FY 2023)
Epigral (NSE:EPIGRAL) Full Year 2024 Results
Key Financial Results
- Revenue: ₹19.4b (down 12% from FY 2023).
- Net income: ₹1.96b (down 45% from FY 2023).
- Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.
- EPS: ₹47.13 (down from ₹85.03 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Epigral shares are up 4.3% from a week ago.
Risk Analysis
Be aware that Epigral is showing 3 warning signs in our investment analysis that you should know about...
Valuation is complex, but we're helping make it simple.
Find out whether Epigral is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:EPIGRAL
Epigral
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally.
Mediocre balance sheet with questionable track record.